Where drugs exhibit reduced bioavailability due to poor solubility, the cause is often intrinsically linked with particle size. Reducing the particle size increases the surface area for a given volume, and may immediately produce improvements in solubility and the rate of dissolution. Both factors will potentially increase bioavailability.
There are several strategies and delivery technologies that use particle size reduction as a route to successful dosage formulation, and we have working partnerships with a number of companies who specialise in reducing particle size in APIs and providing the associated analytical services.